Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)

• Company Description    MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. Number of Employees: 341

• Price / Volume Information    Yesterday's Closing Price: $1.61 Daily Weekly Monthly 20 Day Moving Average: 1,987,442 shares Shares Outstanding: 63.26 (millions) Market Capitalization: $101.85 (millions) Beta: 1.51 52 Week High: $3.60 52 Week Low: $0.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.67% 16.86% 12 Week -8.00% -9.48% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9704 MEDICAL CENTER DRIVE - Rockville,MD 20850 USA ph: 301-251-5172 fax: 301-251-5321 info@macrogenics.com http://www.macrogenics.com

• General Corporate Information    Officers Scott Koenig - Chief Executive Officer;President and Director James Karrels - Senior Vice President;Chief Financial Officer and Beth Smith - Vice President; Controller and Treasurer Karen Ferrante - Director William Heiden - Director Peer Information MacroGenics, Inc. (BJCT) MacroGenics, Inc. (CADMQ) MacroGenics, Inc. (APNO) MacroGenics, Inc. (UPDC) MacroGenics, Inc. (IMTIQ) MacroGenics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 556099109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 63.26 Most Recent Split Date: (:1) Beta: 1.51 Market Capitalization: $101.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.52 Price/Cash Flow: - Price / Sales: 0.80 EPS Growth vs. Year Ago Period: -70.00% vs. Previous Quarter: 147.37% Sales Growth vs. Year Ago Period: -34.21% vs. Previous Quarter: 227.50% ROE 12/31/25 - - 09/30/25 - -98.30 06/30/25 - -40.24 ROA 12/31/25 - - 09/30/25 - -30.28 06/30/25 - -14.62 Current Ratio 12/31/25 - - 09/30/25 - 5.22 06/30/25 - 5.26 Quick Ratio 12/31/25 - - 09/30/25 - 5.02 06/30/25 - 5.02 Operating Margin 12/31/25 - - 09/30/25 - -59.46 06/30/25 - -21.99 Net Margin 12/31/25 - - 09/30/25 - -59.46 06/30/25 - -21.99 Pre-Tax Margin 12/31/25 - - 09/30/25 - -58.64 06/30/25 - -21.36 Book Value 12/31/25 - - 09/30/25 - 1.06 06/30/25 - 0.74 Inventory Turnover 12/31/25 - - 09/30/25 - 4.57 06/30/25 - 3.95 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©